Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital of Soochow University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
330 fő, tervezett
Kezdés
2024. dec. 16.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Letermovir (0-24w)
  • Letermovir (0-14w)
A regiszteradat frissítve
2026. január 21.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults about to have their first stem cell transplant from a donor (allo-HSCT). They must carry past CMV infection and have a high risk of CMV coming back.

Életkor
18 years or older
Nem
All sexes can join
A betegség stádiuma
Planned first allogeneic stem cell transplant with at least one high-risk factor for CMV reactivation: half-compatible family donor, donor with a not fully compatible tissue type (HLA), or unrelated donor; cord blood as the main stem cell source; conditioning with total body irradiation (TBI); or GVHD prevention with alemtuzumab or high-dose ATG.
Korábbi kezelés
No earlier allogeneic stem cell transplant. No investigational drug within 28 days before joining. No cidofovir, CMV immune globulin or experimental CMV antiviral drugs within 28 days before or during the study. No past or current CMV vaccine or CMV drug study.
Biomarker vagy leletérték
CMV antibody test positive (CMV seropositive) before the transplant.

A részvétel fő kizáró okai

  • CMV in the blood (viremia) at any time before joining, or CMV organ disease within 6 months
  • Severe liver disease (Child-Pugh Class C) or kidney failure with creatinine clearance < 10 mL/min
  • Needing a breathing machine or unstable blood pressure and circulation at joining
  • Positive HIV test, active hepatitis C, or hepatitis B surface antigen positive
  • Pregnant, breastfeeding, or planning pregnancy within 90 days after the last dose

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • The patients have decided to undergo an initial allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  • The patients are ≥18 years old
  • The patients are CMV seropositive prior to transplantation
  • The patients have at least one high-risk factor for CMV reactivation, including:; (1) Haploidentical transplantation, HLA-mismatched transplantation, or unrelated donor transplantation; (2) The primary source of stem cells is cord blood. (3) A conditioning regimen including total body irradiation (TBI). (4) A GVHD prophylaxis regimen containing alemtuzumab or high-dose anti-thymocyte globulin (ATG)
  • The patients are able to comply with the study visit schedule, understand and agree to adhere to all protocol requirements, and have voluntarily signed the informed consent form to participate in the study
  • The patients have no plans for reproduction from the date of consent until 90 days after the last dose of the study treatment

Ki nem vehet részt

  • Patients who have previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  • Patients with evidence of CMV viremia at any time prior to enrollment
  • Patients with a history of CMV end-organ disease within 6 months prior to enrollment
  • Patients who received any investigational drug therapy within 28 days prior to enrollment
  • Patients who received or plan to receive any of the following treatments within 28 days prior to enrollment or during the study: cidofovir, CMV immune globulin, or any experimental CMV antiviral drugs/biological therapies
  • Patients who previously participated or are currently participating in any study involving a CMV vaccine or other CMV investigational drugs, or who plan to participate in such studies during this trial
  • Patients who are pregnant or breastfeeding at the time of enrollment or planning to become pregnant within 90 days after the last dose of study medication
  • Patients with suspected or known allergy to letermovir or any active or inactive components of similar drugs
  • Patients with severe hepatic impairment (defined as Child-Pugh Class C)
  • Patients with active solid malignancies, except for localized basal cell or squamous cell carcinoma of the skin or a condition currently under treatment (e.g., lymphoma)
  • Patients with end-stage renal disease with a creatinine clearance < 10 mL/min
  • Patients who test positive for human immunodeficiency virus antibodies (HIV-Ab) at any time prior to randomization, or who test positive for hepatitis C virus antibodies (HCV-Ab) with detectable HCV RNA, or for hepatitis B surface antigen (HBsAg) within 90 days prior to randomization. Laboratory testing for HIV, HBV, or HCV is allowed using locally acceptable methods
  • Patients requiring mechanical ventilation or experiencing hemodynamic instability at the time of enrollment

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

After allogeneic hematopoietic stem cell transplantation (allo-HSCT), recipients are immunocompromised and at increased risk of complications, including cytomegalovirus (CMV) infection. International clinical guidelines for the management of CMV infection post-allo-HSCT recommend three main strategies: minimizing infection risk, prevention, and preemptive therapy. However, traditional antiviral agents have not been approved for CMV prophylaxis in allo-HSCT recipients and are associated with significant adverse effects and the development of resistance, leaving the CMV prevention needs of this patient population unmet. Recent studies have demonstrated that letermovir prevents potent and highly specific antiviral activity against CMV, and it has been approved for CMV prophylaxis within the first 100 days post-allo-HSCT. Furthermore, evidence suggests that extending letermovir administration up to 28 weeks further reduces the risk of CMV infection in the later post-transplant period without increasing drug-related mortality. In China, the post-allo-HSCT CMV prevention strategy faces challenges such as limited treatment options, unclear guideline recommendations, non-standardized drug usage in certain medical institutions, and insufficient monitoring. This study aims to provide robust, evidence-based support for the use of letermovir in high-risk CMV reactivation among adult allo-HSCT recipients, thereby broadening clinical treatment choices.

A vizsgálat 2 csoportja

  • Intervention GroupA vizsgált kezelés

    The patient will begin receiving prophylactic treatment with letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg orally once daily. If administered in combination with cyclosporine, the letermovir dose should be reduced to 240 mg orally once daily. Treatment will continue until 24 weeks post-transplant (approximately 170 days). During hospitalization, the study nurse will distribute the medication to the patient according to the treatment protocol and provide guidance on proper administration. The nurse will ensure the patient adheres to the prescribed dosing schedule and will document both the medication distribution and adherence.

    Kezelés: Letermovir (0-24w)

  • Control GroupEgyéb csoport

    The patient will begin prophylactic treatment with letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg orally once daily. If used in combination with cyclosporine, the letermovir dose should be reduced to 240 mg orally once daily. The treatment will continue for up to 14 weeks post-transplant (approximately 100 days). In addition, the usage of the medication will be carefully monitored and documented.

    Kezelés: Letermovir (0-14w)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Clinical Study on the Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. január 21.